0P8 Stock Chart & Stats
€281.40
€1.20(0.43%)
At close: 4:00 PM EDT
€281.40
€1.20(0.43%)
Day’s Range― - ―
52-Week Range€193.10 - €306.40
Previous CloseN/A
Volume0.00
Average Volume (3M)81.00
Market Cap
€10.92B
Enterprise Value€12.05K
Total Cash (Recent Filing)€658.79M
Total Debt (Recent Filing)€212.71M
Price to Earnings (P/E)78.5
Beta-0.05
Next Earnings
Nov 04, 2026EPS Estimate
1.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)4.09
Shares Outstanding39,389,423
10 Day Avg. Volume9
30 Day Avg. Volume81
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)8.48
Price to Sales (P/S)8.62
P/FCF Ratio69.17
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€307.44Price Target Upside9.25% Upside
Rating ConsensusHold
Number of Analyst Covering6
EPS Forecast (FY)4.1
Revenue Forecast (FY)€1.37B
Bulls Say, Bears Say
Bulls Say
Clinical Evidence And Market SharePenumbra's leading thrombectomy device has clinical evidence supporting conversion from drug therapy, which is likely to accelerate market share gains in thrombectomy and expand addressable patient volumes.
Product AdoptionStrong US adoption of the Ruby XL and new coil technology is driving embolization revenue growth and broadening the company's commercial base.
Strategic Acquisition SynergiesThe proposed acquisition by Boston Scientific aligns Penumbra's products with the buyer's cardiac portfolio, enabling synergies in peripheral thrombectomy and embolization and supporting a premium valuation.
Bears Say
Financing And Leverage ConcernsThe deal's use of cash, new debt and stock increases leverage for the combined company and could constrain financial flexibility after closing.
Limited Upside Due To Takeover DynamicsPending acquisition dynamics are expected to keep the stock trading near the agreed deal price, reducing standalone upside and prompting analyst rating downgrades.
Regulatory And Approval RiskA delay in regulatory approval for a key device has weighed on stroke-related sales and increases near-term revenue and execution uncertainty in the thrombectomy business.
0P8 FAQ
What was Penumbra’s price range in the past 12 months?
Penumbra lowest stock price was €193.10 and its highest was €306.40 in the past 12 months.
What is Penumbra’s market cap?
Penumbra’s market cap is €10.92B.
When is Penumbra’s upcoming earnings report date?
Penumbra’s upcoming earnings report date is Nov 04, 2026 which is in 68 days.
How were Penumbra’s earnings last quarter?
Penumbra released its earnings results on Jul 30, 2026. The company reported €0.763 earnings per share for the quarter, missing the consensus estimate of €1.007 by -€0.244.
Is Penumbra overvalued?
According to Wall Street analysts Penumbra’s price is currently Undervalued.
Does Penumbra pay dividends?
Penumbra does not currently pay dividends.
What is Penumbra’s EPS estimate?
Penumbra’s EPS estimate is 1.04.
How many shares outstanding does Penumbra have?
Penumbra has 39,389,423 shares outstanding.
What happened to Penumbra’s price movement after its last earnings report?
Penumbra reported an EPS of €0.763 in its last earnings report, missing expectations of €1.007. Following the earnings report the stock price went up 0.289%.
Which hedge fund is a major shareholder of Penumbra?
Currently, no hedge funds are holding shares in DE:0P8
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Penumbra Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
€307.44 (9.25% Upside)
€307.44 (9.25% Upside)
Blogger Sentiment
Bearish
DE:0P8 Sentiment 67%
Sector Average 60%
Sector Average 60%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
37.06%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
17.91%
Trailing 12-Months
Company Description
Penumbra
Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. It offers computer-assisted vacuum thrombectomy; peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX, BENCHMARK, BMX, DDC, Access25; MIDWAY, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization device, aspiration tubing, aspiration pump, and other components and accessories under the Penumbra RED, SENDit, JET, ACE, BMX, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that include the Penumbra Coil 400, for the treatment of aneurysms and other complex lesions, detachable coils of neurovascular lesions under the Penumbra SMART COIL, SwiftSET, and Penumbra SwiftPAC Coil brands; and POD400 and PAC400 brands. In addition, it provides peripheral embolization products, such as Ruby Embolization Platform, which consists of detachable coils for peripheral applications; Ruby LP and XL Embolization Platform; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; Packing Coil LP; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers neurosurgical tools comprising the Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. It sells its products through direct sales organizations and distributors. The company was incorporated in 2004 and is based in Alameda, California.
0P8 Stock 12 Month Forecast
Average Price Target
€307.44
▲(9.25% Upside)










